An abridged version of the REVEAL risk calculator, the REVEAL Lite 2, represents a simpler and accurate tool for predicting mortality risk in patients with pulmonary arterial hypertension.
Oral combination therapy does not appear to help achieve or maintain low risk status in most treatment-naive patients with pulmonary arterial hypertension.
Nighttime nasal high flow therapy at 20 L/min reduced sympathetic drive in patients with precapillary pulmonary hypertension and obstructive sleep apnea.
Pulmonary arterial compliance was found to be strongly associated with all-cause mortality and clinical worsening in patients with systemic lupus erythematosus-associated pulmonary arterial hypertension.
The surgical management of patients with massive pulmonary embolism and high-risk submassive PE was found to be safe and highly effective for achieving right ventricular recovery.
Pulmonary artery denervation in patients with residual chronic thromboembolic pulmonary hypertension after pulmonary endarterectomy was associated with improved hemodynamics and clinical and functional status compared with medical therapy.
Although higher body mass index is causally associated with higher pulmonary artery pressure, it is not associated with pulmonary vascular remodeling.
The sNDA is supported by data from the multicenter, double-blind, placebo-controlled phase 3 INCREASE study.
The pulmonary pathobiology of patients who died from respiratory failure caused by COVID-19 vs influenza was found to be distinct.
Individuals of Hispanic/Latino background with known peripheral artery disease (PAD) have the lowest use of all classes of cardiovascular medications.